The innovative drug sector is emerging as a new driver of export growth, fueled largely by cross-border out-licensing, with the NewCo model and direct overseas commercialization also gaining traction, ...

ProKidney Corp. faces weak Phase 2 rilparencel data and a cash runway only to mid-2027 ahead of pivotal 2027 Phase 3 results.

ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on ...

On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic ...

KNOXVILLE, Tenn.-- (BUSINESS WIRE)--Aug 14, 2026-- ...

BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...

Seattle biotech InduPro has raised $77 million and dosed its first patient in a Phase 1 trial of an experimental cancer drug, ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset ...

In July 2026, the Company received Human Research Ethics Committee (HREC) approval in Australia for the Phase I clinical trial of AN4035 as monotherapy and in combination with cetuximab, in patients ...

A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a portion of Neurimmune’s royalty interest in ...

Roche's Q2 results show 5% revenue growth, margin upside and key pipeline catalysts ahead. Click to read my analysis.

Enrollment and dosing underway in study of investigational PSMA-targeted fluorescent agent for prostate cancer.